SunTrust Banks Weighs in on TESARO Inc’s Q1 2018 Earnings (TSRO)
TESARO Inc (NASDAQ:TSRO) – Equities researchers at SunTrust Banks decreased their Q1 2018 earnings estimates for TESARO in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings of ($2.73) per share for the quarter, down from their prior forecast of ($2.11). SunTrust Banks currently has a “Buy” rating and a $160.00 target price on the stock. SunTrust Banks also issued estimates for TESARO’s Q2 2018 earnings at ($2.45) EPS, Q3 2018 earnings at ($2.74) EPS, Q4 2018 earnings at ($2.58) EPS, FY2018 earnings at ($10.51) EPS, FY2019 earnings at ($7.88) EPS, FY2020 earnings at ($4.11) EPS, FY2021 earnings at $3.29 EPS and FY2022 earnings at $7.04 EPS.
A number of other equities analysts have also commented on the stock. Morgan Stanley reissued an “overweight” rating and issued a $165.00 price target (down previously from $181.00) on shares of TESARO in a report on Wednesday, November 8th. Citigroup reissued a “buy” rating and issued a $135.00 price target (down previously from $216.00) on shares of TESARO in a report on Wednesday, December 20th. HC Wainwright reissued a “buy” rating and issued a $158.00 price target on shares of TESARO in a report on Friday, January 12th. Cowen decreased their price target on shares of TESARO from $125.00 to $80.00 and set a “market perform” rating on the stock in a report on Tuesday, January 2nd. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $150.00 target price (down previously from $190.00) on shares of TESARO in a report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $133.39.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). The company had revenue of $48.02 million during the quarter, compared to the consensus estimate of $51.78 million. TESARO had a negative return on equity of 112.72% and a negative net margin of 222.15%.
A number of institutional investors and hedge funds have recently made changes to their positions in TSRO. Exane Derivatives boosted its position in TESARO by 137.1% during the 4th quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 1,123 shares during the period. Toronto Dominion Bank boosted its position in TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares during the period. Bourgeon Capital Management LLC purchased a new stake in TESARO during the 4th quarter valued at $211,000. Fox Run Management L.L.C. purchased a new stake in TESARO during the 4th quarter valued at $218,000. Finally, Commonwealth Equity Services Inc purchased a new stake in TESARO during the 3rd quarter valued at $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.